Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | ARG1 | P05089 | 1/20 | 0.33 |
| ▸ | ARG2 | P78540 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26109677 | 0.88 | ALDH1A1 (0.35) | ALDH1A1MAPK1L3MBTL1KDM4E | |
| SCHEMBL1054527 | 0.86 | — | — | |
| SCHEMBL14067192 | 0.82 | ALDH1A1 (0.40) | ALDH1A1MAPK1TSHRTP53GAA | |
| SCHEMBL26113721 | 0.82 | L3MBTL1 (0.33) | ALDH1A1L3MBTL1KDM4E | |
| SCHEMBL12355646 | 0.80 | TSHR (0.39) | ALDH1A1MAPK1TSHRHDAC1HDAC6 | |
| SCHEMBL19924672 | 0.80 | ALDH1A1 (0.39) | ALDH1A1MAPK1TSHRGAA | |
| SCHEMBL21592448 | 0.80 | ALDH1A1 (0.39) | ALDH1A1MAPK1TSHRTP53GAA | |
| SCHEMBL28903229 | 0.80 | NOS3 (0.38) | ALDH1A1RAB9A | |
| SCHEMBL21815374 | 0.80 | NOS3 (0.38) | ALDH1A1TSHRSMN1; SMN2KDM4E | |
| SCHEMBL26923701 | 0.79 | KDM4E (0.31) | ALDH1A1SMN1; SMN2L3MBTL1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2378601-B1 | ELECTROLYTE CONTAINING A EUTECTIC MIXTURE AND A SPECIFIC NITRILE COMPOUND, AND ELECTROCHEMICAL DEVICE COMPRISING THE SAME | LG CHEMICAL LTD (KR) | 2016-03-30 | — | — | EP | claimed |
| EP-2378601-A2 | ELECTROLYTE CONTAINING EUTECTIC MIXTURE AND NITRILE COMPOUND AND ELECTROCHEMICAL DEVICE FURNISHED WITH THE SAME | LG Chem, Ltd. (KR) | 2011-10-19 | — | — | EP | claimed |
| US-20100304222-A1 | ELECTROLYTE HAVING EUTECTIC MIXTURE AND NITRILE COMPOUND, AND ELECTROCHEMICAL DEVICE CONTAINING THE SAME | LG ENERGY SOLUTION, LTD. (KR) | 2010-12-02 | — | — | US | claimed |
| US-9954253-B2 | Electrolyte having eutectic mixture and nitrile compound, and electrochemical device containing the same | LG CHEM, LTD. (KR) | 2018-04-24 | — | — | US | disclosed |
| EP-2378601-B1 | ELECTROLYTE CONTAINING A EUTECTIC MIXTURE AND A SPECIFIC NITRILE COMPOUND, AND ELECTROCHEMICAL DEVICE COMPRISING THE SAME | LG CHEMICAL LTD (KR) | 2016-03-30 | — | — | EP | disclosed |
| EP-1577288-B1 | Selective estrogen receptor modulators | EISAI R&D MAN CO LTD (JP) | 2014-07-23 | — | — | EP | disclosed |
| US-8399520-B2 | Selective estrogen receptor modulator | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-03-19 | — | — | US | disclosed |
| EP-2378601-A2 | ELECTROLYTE CONTAINING EUTECTIC MIXTURE AND NITRILE COMPOUND AND ELECTROCHEMICAL DEVICE FURNISHED WITH THE SAME | LG Chem, Ltd. (KR) | 2011-10-19 | — | — | EP | disclosed |
| US-7989451-B2 | Tricyclic 1,2,4-triazine oxides and compositions for therapeutic use in cancer treatments | AUCKLAND UNISERVICES LIMITED (NZ) | 2011-08-02 | — | — | US | disclosed |
| EP-1866292-B1 | TRICYCLIC 1,2,4-TRIAZINE OXIDES AND COMPOSITIONS THEREFROM FOR THERAPEUTIC USE IN CANCER TREATMENTS | AUCKLAND UNISERVICES LTD (NZ) | 2010-12-15 | — | — | EP | disclosed |
| US-20100304222-A1 | ELECTROLYTE HAVING EUTECTIC MIXTURE AND NITRILE COMPOUND, AND ELECTROCHEMICAL DEVICE CONTAINING THE SAME | LG ENERGY SOLUTION, LTD. (KR) | 2010-12-02 | — | — | US | disclosed |
| US-20090325930-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATOR | RADIUS HEALTH, INC. | 2009-12-31 | — | — | US | disclosed |
| US-20090186886-A1 | Tricyclic 1,2,4-Triazine Oxides and Compositions for Therapeutic Use in Cancer Treatments | AUCKLAND UNISERVICES LIMITED (NZ) | 2009-07-23 | — | — | US | disclosed |
| EP-1866292-A1 | TRICYCLIC 1,2,4-TRIAZINE OXIDES AND COMPOSITIONS THEREFROM FOR THERAPEUTIC USE IN CANCER TREATMENTS | Auckland Uniservices Limited (NZ) | 2007-12-19 | — | — | EP | disclosed |
| WO-2006104406-A1 | TRICYCLIC 1,2,4-TRIAZINE OXIDES AND COMPOSITIONS THEREFROM FOR THERAPEUTIC USE IN CANCER TREATMENTS | AUCKLAND UNISERVICES LIMITED (NZ) | 2006-10-05 | — | — | WO | disclosed |
| EP-1577288-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATORS | Eisai Co., Ltd. (JP) | 2005-09-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325930-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATOR | ESR1, GPER1, ESR2 | ALDH1A1 1111/4885MAPK1 1484/4885TSHR 164/4885 |
| US-20090186886-A1 | Tricyclic 1,2,4-Triazine Oxides and Compositions for Therapeutic Use in Cancer Treatments | HIF1AN, HIF1A, HYOU1 | ALDH1A1 512/4885MAPK1 2543/4885TSHR 1741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.